CPT Codes 36465 & 36466 are here

Reimbursement support services

If your practice uses Varithena®, you have access to a wide range of reimbursement support services through the Varithena Solutions Center™. Highly trained reimbursement counselors provide expertise, resources, and customized support to facilitate the submission of a clean claim. 


Services of the Varithena Solutions Center™ include:

Varithena® Co-pay Assistance Program support

  • Check patient eligibility
  • Work with specialty pharmacies to process co-pay cases opened through the Varithena®  Co-pay Assistance Program
  • Coordinate with pharmacies to ensure Varithena® is shipped to your practice

Specialty Pharmacy Information for Patients

  • Receive a call from a specialty pharmacy to collect a co-pay for your patient’s treatment
  • Download the information sheet to learn more about the specialty pharmacy benefit

Reimbursement/prior authorization (PA) support

  • Conduct patient-specific benefits verifications on the Varithena® procedure 
  • Provide guidance on PA documentation process
  • Submit PA documentation and follow up with payers
  • Review Letter of Medical Necessity documentation against payer guidelines

Product ordering support

  • Provide guidance on payer- and patient-specific distribution options

Billing, coding, and claims support

  • Provide billing and coding guidance prior to submitting Varithena® claims
  • Educate providers on payer processes, documentation, and timelines 
  • Identify appeal options for denied or underpaid claims
  • Initiate appeals and follow up with payers

Product support

  • Connect to BTG Medical Affairs
  • Address product complaints
  • Facilitate adverse events reporting

Ordering Varithena®

Varithena® can be ordered through BTG International or another approved specialty distributor for buy-and-bill. See the list and contact information below.

Reminder: Do you have the supplies you need?

A new Varithena® administration pack is needed for each patient. It is recommended that you have an additional Varithena® bi-canister and administration packs on hand at all times.

If you wish to return product that you have received, please review the  Returned Goods Policy .


Specialty Distributor Contact Information
(alphabetical order)

Specialty Distributor Customer Telephone Fax Web Orders
ASD Healthcare Hospitals 800-746-6273 800-547-9413
Cardinal Health Specialty Distribution Physician Offices, Hospitals 866-677-4844 888-345-4916
McKesson Plasma and Biologics Hospitals 877-625-2566 888-752-7626 Please Call for Ordering
McKesson Specialty Health Physician Offices 855-477-9800 800-289-2985
Other Contact Customer Telephone Fax Web Orders
BTG Direct Physician Offices, Hospitals 855-971-8346 (VEIN) 877-626-9910 Please email:
Click here for more information on submitting Varithena® claims

Contact your Territory
Sales Manager for more information.
Varithena Solutions Center™
1-855-971-VEIN (8346)
Monday through Friday,
8 am to 8 pm ET
Enter security code:
 Security code


Varithena®  (polidocanol injectable foam) is indicated for the treatment of incompetent great saphenous veins, accessory saphenous veins and visible varicosities of the great saphenous vein (GSV) system above and below the knee. Varithena®  improves the symptoms of superficial venous incompetence and the appearance of visible varicosities.


The use of Varithena®  is contraindicated in patients with known allergy to polidocanol and those with acute thromboembolic disease.

Severe allergic reactions have been reported following administration of liquid polidocanol, including anaphylactic reactions, some of them fatal. Observe patients for at least 10 minutes following injection and be prepared to treat anaphylaxis appropriately. Intra-arterial injection or extravasation of polidocanol can cause severe necrosis, ischemia or gangrene. Patients with underlying arterial disease may be at increased risk for tissue ischemia. If intra-arterial injection of polidocanol occurs, consult a vascular surgeon immediately.

Varithena®  can cause venous thrombosis. Follow administration instructions closely and monitor for signs of venous thrombosis after treatment. Patients with reduced mobility, history of deep vein thrombosis or pulmonary embolism, or recent (within 3 months) major surgery, prolonged hospitalization, or pregnancy are at increased risk for developing thrombosis. The most common adverse events observed were pain/discomfort in extremity, retained coagulum, injection site hematoma or pain, common femoral vein thrombus extension, superficial thrombophlebitis, and deep vein thrombosis.

Physicians administering Varithena®  must be experienced with venous procedures, possess a detailed working knowledge of the use of the duplex ultrasound in venous disease and be trained in the administration of Varithena® .

See Full Prescribing Information for Varithena®.

Follow Us